[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610299":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":29,"centralContacts":10,"locations":33,"responsibleParty":52,"collaborators":55,"id":61,"slug":10,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":10,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Males",null,[12,13],"Drug: Dronabinol","Drug: Placebo",{"label":15,"type":6,"description":10,"interventionNames":16},"Females",[12,13],[18,25],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","Dronabinol","Oral dronabinol capsules (40 mg)",[15,9],[24],"Marinol",{"type":19,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Placebo","Matched placebo capsules",[15,9],[30],{"name":31,"affiliation":5,"role":32},"Erin Martin, Ph.D.","PRINCIPAL_INVESTIGATOR",[34],{"facility":5,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Charleston","South Carolina","29403","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-79.93275,32.77632,{"lat":45,"lon":44},[48],{"name":31,"role":49,"phone":50,"phoneExt":10,"email":51},"CONTACT","843-876-3528","marterin@musc.edu",{"type":32,"investigatorFullName":53,"investigatorTitle":54,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Erin Martin","Research Assistant Professor-Faculty",[56,59],{"name":57,"class":58},"National Institutes of Health (NIH)","NIH",{"name":60,"class":58},"National Institute on Drug Abuse (NIDA)","100610299",false,"NCT07225777","Sex Differences in Neurobehavioral Response to THC","Sex Differences in Neurobehavioral Response to Acute THC in Adults With Cannabis Use Disorder","Inclusion Criteria:\n\n* Age 21-45\n* DSM-5 criteria for CUD\n* Cannabis use ≥4 days\u002Fweek\n* THC-positive urine\n* BMI 18-30\n* Regular menstrual cycle (females)\n* Willingness to use non-hormonal birth control (females)\n\nExclusion Criteria:\n\n* Lifetime psychotic or bipolar disorder\n* Recent drug use other than cannabis\n* Current psychotropic medication\n* Treatment-seeking for SUD\n* Current psychiatric disorder (except mild alcohol, nicotine, or caffeine use disorder)\n* Pregnancy\u002Fnursing\n* MRI contraindications","ALL","21 Years","45 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"PHASE2","This study investigates sex differences in reward processing following acute THC administration in adults with cannabis use disorder (CUD). Using multimodal neuroimaging (MRS and fMRI), the study will assess glutamate levels in the nucleus accumbens and striatal BOLD response to monetary reward anticipation. Participants will complete two counterbalanced dosing sessions (oral THC 40 mg vs. placebo).",[78],"Cannabis Use Disorder",[80],"Substance Use","2026-05-04",{"date":83,"type":84},"2026-05-06","ACTUAL",{"date":86,"type":84},"2026-04-27",{"date":88,"type":72},"2027-12-31",{"name":5,"class":6},1]